"SB: Yes, I would expect to see interim announcements and data points. Again, about management at Celldex, you're talking about a team that has shown itself to be exceedingly flexible and adroit in making sure that shareholders are kept informed."
J20, what is worse than that, in the same conversation BHO refers to, and judges todays America for what happened 200 - 300 years ago, suggesting racism from then is not erased today.
This sounds rather familiar..., at least this time he is not reaching back several thousand years to make his case. In the face of great racial progress in our lifetimes, this man stokes the race divide constantly for political gain. In my opinion, he has a race problem himself. He has become the great divider.
Well Long, this really closes the loop on the story of Rintega, and make it much easier to explain to the FDA.
This is impeccable timing for Celldex.
Questions: Other than needing to report continued progress from ReAct at ASCO, do you see other hurdles Celldex must clear before they ask for FDA approval? And how is the FDA likely to view the P3 trial currently underway? Can they give approval based on ReAct and keep the P3 in tact? Or might they delay approval due to the ongoing P3 and the potential of disturbing that trial?
Thanks in advance.
Eventually there will be reports on trial results just about every month with Celldex. In the spirit of hockey season, I love how many shots on goal Celldex is taking.
I think yes, it is. Just shows PD-1 inhibitors are not going to do it alone, and will need Varli or similar boosters to get the results everyone hoping for, and cancer patients need.
Well now. You shorts are crazy.
Enough already. This man murdered a bunch of people. Premeditated murder. Mass murder.
What the president said about the American deserter from the lawn of the WH, proves this president will lie about ANYTHING. Anything at all. This President is not to be trusted.
What he said today, what he says tomorrow, and what he has said in the past, is not to be trusted. EVER.
Compared to Obama, Nixon was an amateur lier. And if you disagree, maybe we should start listing his lies on a regular basis.
And you micro, try saying a little more than calling people racist.
Dr Reardon points out that no immunotherapy approach has ever shown a statistically significant improvement in survival in glioblastoma in a randomized, controlled study.
He adds that the Celldex data “provide very strong support” that immunotherapy might have a significant impact on glioblastoma the way it has for some other cancers of the skin and lungs. Perhaps, for instance, rindo could be combined with other drugs, like so-called “checkpoint inhibitors,” that rev up the immune system to fight cancer, and have a major impact on the disease. “These data set the stage for the next steps,” he says.
Even you leftist out there are going to cringe when you hear the details of what they have been up to.
This game of pay to play is not going away, this time.
Longvrts, love the post, and cant agree more. I know you do not often speak of SP, but in your opinion, what are your thoughts on what is holding back the current SP?
You have got to be kidding. This man is watching his house burn, and all he can think of is the leaking faucet.
Is anyone else getting the feeling that BHO is pleased with how things are going in the Middle East, with Islamic extremist challenging for full control through out? Reasonable people who voted for him have got to be second guessing that little move. This man is intent on a full power structure change throughout the world. A change that puts America's or Liberty's enemies on par with Liberty loving countries. And yes, I really think that is what he is doing. God help us all. It's going to get worse for millions of people.
Starting to feel like 1936 all over again.
"Mara Goldstein of Cantor Fitzgerald pointed out that this study was different than previous studies due to its larger population of enrolled patients. Moreover, the new data showed “a statistically significant difference in overall survival at 12 and 18 months.” On June 1, Mara Goldstein reiterated a Buy rating on Celldex Therapeutics with a $38 price target. Following the data released on the GBM study, Goldstein believes that “commercialization [of the drug] is likely.” Goldstein is “awaiting clarity on the registration path for Rintega,” but believes the therapy is heading towards a New Drug Application as it has already been designated as a breakthrough drug. Goldstein concluded, “We continue to like shares of Celldex based on the depth and breadth candidates in numerous clinical trials.”"
The Celldex GBM P3 is for newly diagnosed patients. The ReAct study at ASCO is for recurrent patients.
No need to wait any longer, recurrent patients have no better options, and newly diagnosed patients with the EGFRvIII protein marker will likely want Rintega too. They may also want Rintega in combo with a PD-1, PD-1L, Varli, or something along those lines.